Johann S. Bergholz

Johann S. Bergholz

Auto-generated profile, based on publicly available information

Johann S. Bergholz

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
SGShom Goel
Shom Goel
JBJohann S. Bergholz
Johann S. Bergholz
JZJean J. Zhao
Jean J. Zhao

31 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
Qiwei WangQiwei Wang
Qiwei Wang
JBJohann S. Bergholz
Johann S. Bergholz
LDLiya Ding
Liya Ding
ZLZiying Lin
Ziying Lin
SKSheheryar K. Kabraji
Sheheryar K. Kabraji
JZJean J. Zhao
Jean J. Zhao
PARP inhibitors (PARPi) have drastically changed the treatment landscape of advanced ovarian tumors withBRCAmutations. However, the impact of this class of inhibitors in patients with advancedBRCA-mutant breast cancer is relatively modest. Using a syngeneic genetically-engineered mouse model of breast tumor driven byBrca1deficiency, we show that tumor-associated macrophages (TAMs) blunt PARPi efficacy both in vivo and in vitro. Mechanistically, BRCA1-deficient breast tumor cells induce pro-tumor polarization of TAMs, which in turn suppress PARPi-elicited DNA damage in tumor cells, leading to reduced production of dsDNA fragments and synthetic lethality, hence impairing STING-dependent anti-tumor immunity. STING agonists reprogram M2-like pro-tumor macrophages into an M1-like anti-tumor state in a macrophage STING-dependent manner. Systemic administration of a STING agonist breaches multiple layers of tumor cell-mediated suppression of immune cells, and synergizes with PARPi to suppress tumor growth. The therapeutic benefits of this combination require host STING and are mediated by a type I IFN response and CD8+T cells, but do not rely on tumor cell-intrinsic STING. Our data illustrate the importance of targeting innate immune suppression to facilitate PARPi-mediated engagement of anti-tumor immunity in breast cancer.

19 April 2023 in Nature
Verified
Journal Article
Closed access
PDF file
JBJohann S. Bergholz
Johann S. Bergholz
Qiwei WangQiwei Wang
Qiwei Wang
QWQi Wang
Qi Wang
MRMichelle Ramseier
Michelle Ramseier
SPSanjay Prakadan
Sanjay Prakadan
JZJean J. Zhao
Jean J. Zhao

15 March 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
GGGiorgio Gaglia
Giorgio Gaglia
SKSheheryar Kabraji
Sheheryar Kabraji
DRDanae Rammos
Danae Rammos
YDYang Dai
Yang Dai
AVAna Verma
Ana Verma
SSSandro Santagata
Sandro Santagata

21 February 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CGCristina Guarducci
Cristina Guarducci
ANAgostina Nardone
Agostina Nardone
DRDouglas Russo
Douglas Russo
ZNZsuzsanna Nagy
Zsuzsanna Nagy
CHCapucine Heraud
Capucine Heraud
RJRinath Jeselsohn
Rinath Jeselsohn
Purpose: Resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) is a clinical challenge in estrogen receptor (ER)-positive (ER+) breast cancer. Cyclin-dependent kinase 7 (CDK7) is a candidate target in endocrine-resistant ER+ breast cancer models and selective CDK7 inhibitors (CDK7i) are in clinical development for the treatment of ER+ breast cancer. Nonetheless, the precise mechanisms responsible for the activity of CDK7i in ER+ breast cancer remain elusive. Herein, we sought to unravel these mechanisms. Experimental Design: We conducted multi-omic analyses in ER+ breast cancer models in vitro and in vivo, including models with different genetic backgrounds. We also performed genome-wide CRISPR/Cas9 knockout screens to identify potential therapeutic vulnerabilities in CDK4/6i-resistant models. Results: We found that the on-target antitumor effects of CDK7 inhibition in ER+ breast cancer are in part p53 dependent, and involve cell cycle inhibition and suppression of c-Myc. Moreover, CDK7 inhibition exhibited cytotoxic effects, distinctive from the cytostatic nature of ET and CDK4/6i. CDK7 inhibition resulted in suppression of ER phosphorylation at S118; however, long-term CDK7 inhibition resulted in increased ER signaling, supporting the combination of ET with a CDK7i. Finally, genome-wide CRISPR/Cas9 knockout screens identified CDK7 and MYC signaling as putative vulnerabilities in CDK4/6i resistance, and CDK7 inhibition effectively inhibited CDK4/6i-resistant models. Conclusions: Taken together, these findings support the clinical investigation of selective CDK7 inhibition combined with ET to overcome treatment resistance in ER+ breast cancer. In addition, our study highlights the potential of increased c-Myc activity and intact p53 as predictors of sensitivity to CDK7i-based treatments.

20 June 2016 in Oncotarget
Verified
Journal Article
Open access
AHAnning Han
Anning Han
JLJuan Li
Juan Li
YLYimin Li
Yimin Li
YWYang Wang
Yang Wang
JBJohann Bergholz
Johann Bergholz
ZXZhi-Xiong Jim Xiao
Zhi-Xiong Jim Xiao
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Anning Han1, Juan Li1, *, Yimin Li1, *, Yang Wang1, Johann Bergholz1, Yujun Zhang1, Chenghua Li1, Zhi-Xiong Xiao1 1Center of Growth, Metabolism and Aging, Key Laboratory of Biological Resources and Ecological Environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu 610064, China *These authors have contributed equally to this work Correspondence to: Chenghua Li, e-mail: lichenghua@scu.edu.cn Zhi-Xiong Xiao, e-mail: jimzx@scu.edu.cn Keywords: p63, MM1, c-Myc, protein stability, cell cycle Received: January 07, 2016 Accepted: May 16, 2016 Published: June 20, 2016